10113 related articles for article (PubMed ID: 18159896)
21. [MITF: a genetic key to melanoma and renal cell carcinoma?].
Bertolotto C; Lesueur F; Bressac de Paillerets B
Med Sci (Paris); 2012 Mar; 28(3):258-61. PubMed ID: 22480646
[No Abstract] [Full Text] [Related]
22. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
[TBL] [Abstract][Full Text] [Related]
23. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
[TBL] [Abstract][Full Text] [Related]
24. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population.
Hacker E; Hayward NK; Dumenil T; James MR; Whiteman DC
J Invest Dermatol; 2010 Jan; 130(1):241-8. PubMed ID: 19571821
[TBL] [Abstract][Full Text] [Related]
25. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
[No Abstract] [Full Text] [Related]
26. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations.
Hacker E; Nagore E; Cerroni L; Woods SL; Hayward NK; Chapman B; Montgomery GW; Soyer HP; Whiteman DC
J Invest Dermatol; 2013 Apr; 133(4):1027-33. PubMed ID: 23096702
[TBL] [Abstract][Full Text] [Related]
27. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of Familial Melanoma in Valencia, Spain, Based on the Presence of CDKN2A Mutations and MC1R Variants.
Huerta C; Garcia-Casado Z; Bañuls J; Moragon M; Oliver V; Unamuno B; Requena C; Kumar R; Nagore E
Acta Derm Venereol; 2018 Apr; 98(5):512-516. PubMed ID: 29405243
[TBL] [Abstract][Full Text] [Related]
29. Somatic driver mutations in melanoma.
Reddy BY; Miller DM; Tsao H
Cancer; 2017 Jun; 123(S11):2104-2117. PubMed ID: 28543693
[TBL] [Abstract][Full Text] [Related]
30. Genetic alterations in melanocytic tumors.
Takata M; Saida T
J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
[TBL] [Abstract][Full Text] [Related]
31. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
32. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.
Goldstein AM; Landi MT; Tsang S; Fraser MC; Munroe DJ; Tucker MA
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2208-12. PubMed ID: 16172233
[TBL] [Abstract][Full Text] [Related]
33. Familial melanoma; CDKN2A and beyond.
Gruis NA; van der Velden PA; Bergman W; Frants RR
J Investig Dermatol Symp Proc; 1999 Sep; 4(1):50-4. PubMed ID: 10537008
[TBL] [Abstract][Full Text] [Related]
34. Functional interplay between secreted ligands and receptors in melanoma.
Herraiz C; Jiménez-Cervantes C; Sánchez-Laorden B; García-Borrón JC
Semin Cell Dev Biol; 2018 Jun; 78():73-84. PubMed ID: 28676423
[TBL] [Abstract][Full Text] [Related]
35. BRAF as a melanoma susceptibility candidate gene?
Laud K; Kannengiesser C; Avril MF; Chompret A; Stoppa-Lyonnet D; Desjardins L; Eychene A; Demenais F; Lenoir GM; Bressac-de Paillerets B;
Cancer Res; 2003 Jun; 63(12):3061-5. PubMed ID: 12810628
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of human cutaneous melanoma-derived cell lines.
Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
38. Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013-2018).
Visser M; van der Stoep N; Gruis N
Fam Cancer; 2019 Apr; 18(2):267-271. PubMed ID: 30659395
[No Abstract] [Full Text] [Related]
39. Influence of loss of function MC1R variants in genetic susceptibility of familial melanoma in Spain.
de Torre C; Garcia-Casado Z; Martínez-Escribano JA; Botella-Estrada R; Bañuls J; Oliver V; Mercader P; Azaña JM; Frias J; Nagore E
Melanoma Res; 2010 Aug; 20(4):342-8. PubMed ID: 20539244
[TBL] [Abstract][Full Text] [Related]
40. Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation.
Eliason MJ; Hansen CB; Hart M; Porter-Gill P; Chen W; Sturm RA; Bowen G; Florell SR; Harris RM; Cannon-Albright LA; Swinyer L; Leachman SA
Arch Dermatol; 2007 Nov; 143(11):1409-12. PubMed ID: 18025365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]